Journal articles: 'Anti-metastatic'

1

PA, Steeg. "Nm23: an “anti-metastatic” gene." Advances in Anatomic Pathology 2, no. 1 (January 1995): 55. http://dx.doi.org/10.1097/00125480-199501000-00024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Jiang, Y. L., and Z. P. Liu. "Natural Products as Anti-Invasive and Anti-Metastatic Agents." Current Medicinal Chemistry 18, no. 6 (February 1, 2011): 808–29. http://dx.doi.org/10.2174/092986711794927711.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hung, Wen-Chun. "Anti-metastatic Action of Non-steroidal Anti-inflammatory Drugs." Kaohsiung Journal of Medical Sciences 24, no. 8 (August 2008): 392–97. http://dx.doi.org/10.1016/s1607-551x(08)70162-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ferreira, Adilson Kleber, Vanessa Morais Freitas, Débora Levy, Jorge Luiz Mária Ruiz, Sergio Paulo Bydlowski, Rose Eli Grassi Rici, Otaviano Mendonça R. Filho, Gilberto Orivaldo Chierice, and Durvanei Augusto Maria. "Anti-Angiogenic and Anti-Metastatic Activity of Synthetic Phosphoethanolamine." PLoS ONE 8, no. 3 (March 14, 2013): e57937. http://dx.doi.org/10.1371/journal.pone.0057937.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Lapis, K., J. Timár, K. Pál, L. Kopper, and A. Jeney. "Phenotype of metastatic cells as target for anti-metastatic interventions." European Journal of Cancer and Clinical Oncology 23, no. 11 (November 1987): 1773. http://dx.doi.org/10.1016/0277-5379(87)90627-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Beavis, Paul A., Nicole Milenkovski, John Stagg, Mark J. Smyth, and Phillip K. Darcy. "A2Ablockade enhances anti-metastatic immune responses." OncoImmunology 2, no. 12 (December 2013): e26705. http://dx.doi.org/10.4161/onci.26705.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Stock, Anna-Maria, Gabriele Troost, Bernd Niggemann, Kurt Zanker, and Frank Entschladen. "Targets for Anti-metastatic Drug Development." Current Pharmaceutical Design 19, no. 28 (July 1, 2013): 5127–34. http://dx.doi.org/10.2174/1381612811319280011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Flemming, Alexandra. "Unleashing NK cell anti-metastatic activity." Nature Reviews Drug Discovery 13, no. 4 (April 2014): 257. http://dx.doi.org/10.1038/nrd4297.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Vummidi, Balayeshwanth R., Faiza Noreen, Jawad Alzeer, Karin Moelling, and Nathan W. Luedtke. "Photodynamic Agents with Anti-metastatic Activities." ACS Chemical Biology 8, no. 8 (May 28, 2013): 1737–46. http://dx.doi.org/10.1021/cb400008t.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Hennessy, C., JA Henry, FEB May, BR Westley, B. Angus, and TWJ Lennard. "Expression of anti-metastatic gene nm23." British Journal of Cancer 63, no. 6 (December 1991): 1024. http://dx.doi.org/10.1038/bjc.1991.223.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Gandalovičová, Aneta, Daniel Rosel, Michael Fernandes, Pavel Veselý, Petr Heneberg, Vladimír Čermák, Luboš Petruželka, Sunil Kumar, Victoria Sanz-Moreno, and Jan Brábek. "Migrastatics—Anti-metastatic and Anti-invasion Drugs: Promises and Challenges." Trends in Cancer 3, no. 6 (June 2017): 391–406. http://dx.doi.org/10.1016/j.trecan.2017.04.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Smyth, Mark J., Hideo Yagita, and Grant A. McArthur. "Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma." Journal of Clinical Oncology 34, no. 12 (April 20, 2016): e104-e106. http://dx.doi.org/10.1200/jco.2013.51.3572.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Ohishi, Tomokazu, Yukinari Kato, Mika K. Kaneko, Shun-ichi Ohba, Hiroyuki Inoue, Akiko Harakawa, and Manabu Kawada. "Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation." International Journal of Molecular Sciences 21, no. 17 (August 21, 2020): 6037. http://dx.doi.org/10.3390/ijms21176037.

Full text

Abstract:

The now clinically-used anti-epidermal growth factor receptor (EGFR) monoclonal antibodies have demonstrated significant efficacy only in patients with metastatic colorectal cancer (mCRC), with wild-type Kirsten rat sarcoma viral oncogene homolog (KRAS). However, no effective treatments for patients with mCRC with KRAS mutated tumors have been approved yet. Therefore, a new strategy for targeting mCRC with KRAS mutated tumors is desired. In the present study, we examined the anti-tumor activities of a novel anti-EGFR monoclonal antibody, EMab-17 (mouse IgG2a, kappa), in colorectal cancer (CRC) cells with the KRAS p.G13D mutation. This antibody recognized endogenous EGRF in CRC cells with or without KRAS mutations, and showed a high sensitivity for CRC cells in flow cytometry, indicating that EMab-17 possesses a high binding affinity to the endogenous EGFR. In vitro experiments showed that EMab-17 exhibited antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities against CRC cells. In vivo analysis revealed that EMab-17 inhibited the metastases of HCT-15 and HCT-116 cells in the livers of nude mouse metastatic models, unlike the anti-EGFR monoclonal antibody EMab-51 of subtype mouse IgG1. In conclusion, EMab-17 may be useful in an antibody-based therapy against mCRC with the KRAS p.G13D mutation.

APA, Harvard, Vancouver, ISO, and other styles

14

Attard, Gerhardt. "Anti-androgen monotherapy for metastatic prostate cancer." Lancet Oncology 15, no. 6 (May 2014): 543–44. http://dx.doi.org/10.1016/s1470-2045(14)70159-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Menon, Lata G., Ramadasan Kuttan, and Girija Kuttan. "Anti-metastatic activity of curcumin and catechin." Cancer Letters 141, no. 1-2 (July 1999): 159–65. http://dx.doi.org/10.1016/s0304-3835(99)00098-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Ogasawara, Masaru, Takayuki Matsunaga, Satoshi Takahashi, Ikuo Saiki, and Hideyo Suzuki. "Anti-Invasive and Metastatic Activities of Evodiamine." Biological & Pharmaceutical Bulletin 25, no. 11 (2002): 1491–93. http://dx.doi.org/10.1248/bpb.25.1491.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Jacobsoone-Ulrich, Aurélie, Philippe Jamme, Salim Alkeraye, Véronique Dzwiniel, Emmanuel Faure, Carole Templier, and Laurent Mortier. "Ipilimumab in anti-PD1 refractory metastatic melanoma." Melanoma Research 26, no. 2 (April 2016): 153–56. http://dx.doi.org/10.1097/cmr.0000000000000221.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Konda, Bhavana. "Anti-angiogenic agents in metastatic colorectal cancer." World Journal of Gastrointestinal Oncology 7, no. 7 (2015): 71. http://dx.doi.org/10.4251/wjgo.v7.i7.71.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Reymond, Sébastien, and Janine Cossy. "Migrastatin and analogues: New anti-metastatic agents." Comptes Rendus Chimie 11, no. 11-12 (November 2008): 1447–62. http://dx.doi.org/10.1016/j.crci.2008.08.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Timar, J., K. Fazekas, and E. Raso. "Basic HGF-like peptides have anti-angiogenic and anti-metastatic effects." European Journal of Cancer 37 (April 2001): S78—S79. http://dx.doi.org/10.1016/s0959-8049(01)80771-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Aral, Arzu L. "Anti-Endothelial Antibody Positivity in Metastatic and Non-Metastatic Breast Cancer Patients." Turkish Journal of Immunology 2, no. 1 (April 30, 2014): 9–15. http://dx.doi.org/10.5606/tji.2014.294.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Li, Yao, Zhiqiang Yue, Hua Yu, Xiaojian Liu, Li Tao, Zhijie Zhu, Fangtian Fan, et al. "A spontaneous metastatic mathematical model in mice for screening anti-metastatic agents." Journal of Pharmacological and Toxicological Methods 92 (July 2018): 57–66. http://dx.doi.org/10.1016/j.vascn.2018.03.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Hamsa, T. P., and Girija Kuttan. "Studies on Anti-metastatic and Anti-invasive Effects of Harmine Using Highly Metastatic Murine B16F-10 Melanoma Cells." Journal of Environmental Pathology, Toxicology and Oncology 30, no. 2 (2011): 123–37. http://dx.doi.org/10.1615/jenvironpatholtoxicoloncol.v30.i2.40.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Simeone, Ester, Antonio M. Grimaldi, and Paolo A. Ascierto. "Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma." Melanoma Management 2, no. 1 (February 2015): 41–50. http://dx.doi.org/10.2217/mmt.14.30.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Lee, Sang Yeol. "Anti-Metastatic and Anti-Inflammatory Effects of Matrix Metalloproteinase Inhibition by Ginsenosides." Biomedicines 9, no. 2 (February 17, 2021): 198. http://dx.doi.org/10.3390/biomedicines9020198.

Full text

Abstract:

Matrix metalloproteinases (MMPs) are proteolytic enzymes which cleave extracellular matrix (ECM) and other substrates. They are deeply involved in both cancer metastasis and human chronic inflammatory diseases such as osteoarthritis and Crohn’s disease. Regulation of MMPs is closely associated with signaling molecules, especially mitogen-activated protein kinases (MAPKs), including three representative kinases, extracellular signal regulated kinases (ERK), p38 and c-Jun N-terminal kinases (JNK). Ginseng (Panax sp.) is a plant which has been traditionally used for medicinal applications. Ginsenosides are major metabolites which have potentials to treat various human diseases. In this review, the pharmacological effects of ginsenosides have been rigorously investigated; these include anti-metastatic and anti-inflammatory activities of ginsenosides associated with suppression of MMPs via regulation of various signaling pathways. This will highlight the importance of MMPs as therapeutic targets for anti-metastatic and anti-inflammatory drug development based on ginsenosides.

APA, Harvard, Vancouver, ISO, and other styles

26

Koltai, Tomas. "Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs." F1000Research 4 (July 22, 2015): 297. http://dx.doi.org/10.12688/f1000research.6789.1.

Full text

Abstract:

Objective: To determine the exact role of sodium channel proteins in migration, invasion and metastasis and understand the possible anti-invasion and anti-metastatic activity of repurposed drugs with voltage gated sodium channel blocking properties.Material and methods: A review of the published medical literature was performed searching for pharmaceuticals used in daily practice, with inhibitory activity on voltage gated sodium channels. For every drug found, the literature was reviewed in order to define if it may act against cancer cells as an anti-invasion and anti-metastatic agent and if it was tested with this purpose in the experimental and clinical settings.Results: The following pharmaceuticals that fulfill the above mentioned effects, were found: phenytoin, carbamazepine, valproate, lamotrigine, ranolazine, resveratrol, ropivacaine, lidocaine, mexiletine, flunarizine, and riluzole. Each of them are independently described and analyzed.Conclusions: The above mentioned pharmaceuticals have shown anti-metastatic and anti-invasion activity and many of them deserve to be tested in well-planned clinical trials as adjunct therapies for solid tumors and as anti-metastatic agents. Antiepileptic drugs like phenytoin, carbamazepine and valproate and the vasodilator flunarizine emerged as particularly useful for anti-metastatic purposes.

APA, Harvard, Vancouver, ISO, and other styles

27

DENG, YI, ELISE VERRON, and RAMIN ROHANIZADEH. "Molecular Mechanisms of Anti-metastatic Activity of Curcumin." Anticancer Research 36, no. 11 (November 1, 2016): 5639–48. http://dx.doi.org/10.21873/anticanres.11147.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Hassan, Zeinab K., Maha H. Elamin, Maha H. Daghestani, Sawsan A. Omer, Ebtesam M. Al-Olayan, Mai A. Elobeid, Promy Virk, and Osama B. Mohammed. "Oleuropein Induces Anti-metastatic Effects in Breast Cancer." Asian Pacific Journal of Cancer Prevention 13, no. 9 (September 30, 2012): 4555–59. http://dx.doi.org/10.7314/apjcp.2012.13.9.4555.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Dennis, James W., Sandra L. White, Anne M. Freer, and David Dime. "Carbonoyloxy analogs of the anti-metastatic drug swainsonine." Biochemical Pharmacology 46, no. 8 (October 1993): 1459–66. http://dx.doi.org/10.1016/0006-2952(93)90112-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Ahn, S. C., B. Y. Kim, W. K. Oh, Y. M. Park, H. M. Kim, and J. S. Ahn. "Colorimetric heparinase assay for alternative anti-metastatic activity." Life Sciences 79, no. 17 (September 2006): 1661–65. http://dx.doi.org/10.1016/j.lfs.2006.05.020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Chanvorachote, Pithi, Akkarawut Kowitdamrong, Thidarat Ruanghirun, Boonchoo Sritularak, Chutichot Mungmee, and Kittisak Likhitwitayawuid. "Anti-metastatic Activities of Bibenzyls from Dendrobium pulchellum." Natural Product Communications 8, no. 1 (January 2013): 1934578X1300800. http://dx.doi.org/10.1177/1934578x1300800127.

Full text

Abstract:

Our investigation of the stem of Dendrobium pulchellum resulted in the isolation of four known bibenzyls, chrysotobibenzyl (1), chrysotoxine (2), crepidatin (3) and moscatilin (4). The present study reveals for the first time the ability of these four compounds to facilitate anoikis and inhibit the growth of lung cancer cells in anchorage-independent condition. The preliminary data obtained disclose the inhibitory effect on cancer cell metastasis of the isolated compounds, and provide an important new approach for cancer drug development.

APA, Harvard, Vancouver, ISO, and other styles

32

Michaud, Stephanie, and Barbara J. Gour. "Cathepsin B inhibitors as potential anti-metastatic agents." Expert Opinion on Therapeutic Patents 8, no. 6 (June 1998): 645–72. http://dx.doi.org/10.1517/13543776.8.6.645.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Eisenbach, Lea, Ofer Mandelboim, Erez Bar-Haim, Lior Carmon, Hernan Copcow, Khaled El-Shami, Adrian Paz, et al. "Tumor-associated antigen peptides as anti-metastatic vaccines." Letters in Peptide Science 5, no. 5-6 (October 1998): 323–28. http://dx.doi.org/10.1007/bf02443479.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Altundag, Kadri, Ozden Altundag, Mustafa A. Atik, Cem Boruban, Muzaffer B. Altundag, and Selahattin Turen. "Recent Findings for Anti-Metastatic Potential of Heparin." Clinical and Applied Thrombosis/Hemostasis 12, no. 3 (July 2006): 376–77. http://dx.doi.org/10.1177/1076029606291422.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Dornschneider, G., J. R. Izbicki, K. Hallfeldt, and L. Schweiberer. "Anti-estrogenic therapy in metastatic colo-rectal cancer." European Journal of Cancer 30 (January 1994): S7. http://dx.doi.org/10.1016/0959-8049(94)90685-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Rose, April A. N., Susan M. Armstrong, David Hogg, Marcus O. Butler, Samuel D. Saibil, Diana P. Arteaga, Thiago Pimentel Muniz, et al. "Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy." Journal for ImmunoTherapy of Cancer 9, no. 1 (January 2021): e001642. http://dx.doi.org/10.1136/jitc-2020-001642.

Full text

Abstract:

PurposeAnti-programmed cell death protein 1 (PD1)±anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) immune checkpoint inhibitors (ICIs) are standard therapeutic options for metastatic melanoma. We assessed whether biologic subtype according to primary tumor type or genomic subtype can function as predictive biomarkers for anti-PD1±anti-CTLA4 ICI in patients with advanced melanoma.MethodsWe performed a single-center retrospective cohort analysis of patients who received anti-PD1±anti-CTLA4 ICI for advanced melanoma between 2012 and 2019. Primary tumor type, BRAF and NRAS mutation status, and other covariates were abstracted from chart review. Log-rank tests and multivariable Cox regression models were used to assess differences in clinical progression-free (cPFS) and overall survival (OS).ResultsWe identified 230 patients who received 249 lines of anti-PD1±anti-CTLA4 ICI for unresectable or metastatic disease. Of these patients, 74% were cutaneous, 11% mucosal, 8% unknown primary and 7% acral. BRAF and NRAS mutations were identified in 35% and 28% of patients, respectively. In multivariable analyses of the entire cohort, acral or mucosal primary tumor type, >3 metastatic sites, elevated LDH were predictive of shorter cPFS and OS. Combination ICI therapy was associated with longer cPFS (HR 0.57, 95% CI 0.38 to 0.86, p=0.007) and OS (HR 0.42, 95% CI 0.28 to 0.65, p<0.001). Combination ICI was significantly associated with longer OS in unknown primary and mucosal melanoma. There was a non-significant trend toward longer OS with anti-PD1+anti-CTLA4 in cutaneous melanoma, but not in acral melanoma. In multivariable analyses, combination ICI was associated with longer OS in NRAS (HR 0.24, 95% CI 0.10 to 0.62, p=0.003, n=69) and BRAF V600E/K (HR 0.47, 95% CI 0.24 to 0.90, p=0.024, n=86) mutant melanoma but not BRAF/NRAS wild-type (n=94) melanoma.ConclusionsIn our cohort, primary melanoma tumor type and genomic subtype were independent predictive markers of cPFS and OS for patients with metastatic melanoma receiving anti-PD1 ICI. Primary tumor type and genomic subtype—including NRAS—should be further evaluated in prospective clinical trials to determine their value as predictive markers. Biologic subtypes may facilitate clinical decision-making when recommending combination ICI treatment (anti-PD1±anti-CTLA4) versus anti-PD1 alone for patients with metastatic melanoma.

APA, Harvard, Vancouver, ISO, and other styles

37

Kimura, Yoshiyuki, and Maho Sumiyoshi. "Anti-tumor and anti-metastatic actions of wogonin isolated from Scutellaria baicalensis roots through anti-lymphangiogenesis." Phytomedicine 20, no. 3-4 (February 2013): 328–36. http://dx.doi.org/10.1016/j.phymed.2012.10.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Fakih, Marwan. "Primary Tumor Location Implications on Biological Therapy in Metastatic Colorectal Cancer." Oncology & Hematology Review (US) 13, no. 01 (2017): 30. http://dx.doi.org/10.17925/ohr.2017.13.01.30.

Full text

Abstract:

Anti-epidermal growth factor receptors (anti-EGFRs) have been clinically proven to improve overall survival (OS) when combined with chemotherapy in the settings of extended RAS wild-type metastatic colorectal cancers. In addition, randomized phase III studies have confirmed the superiority of anti-EGFR therapy over bevacizumab in the front-line treatment of extended RAS wild-type metastatic colorectal cancer when it comes to response rate, and in select studies, OS. Recent updates from these clinical trials project convincing evidence that tumor sidedness is yet another predictive marker for response to anti-EGFR therapy. While left colonic RAS wild-type metastatic colorectal cancers derive major clinical benefit from anti-EGFR versus bevacizumab therapy, bevacizumab appears to have clear advantage in RAS wild-type metastatic right-sided tumors. In this review, we summarize recent reports from key clinical trials and their impact on day-to-day clinical practice.

APA, Harvard, Vancouver, ISO, and other styles

39

Owyong, Mark, Jonathan Chou, Renske JE van den Bijgaart, Niwen Kong, Gizem Efe, Carrie Maynard, Dalit Talmi-Frank, et al. "MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy." Life Science Alliance 2, no. 6 (November 14, 2019): e201800226. http://dx.doi.org/10.26508/lsa.201800226.

Full text

Abstract:

Metastasis, the main cause of cancer-related death, has traditionally been viewed as a late-occurring process during cancer progression. Using the MMTV-PyMT luminal B breast cancer model, we demonstrate that the lung metastatic niche is established early during tumorigenesis. We found that matrix metalloproteinase 9 (MMP9) is an important component of the metastatic niche early in tumorigenesis and promotes circulating tumor cells to colonize the lungs. Blocking active MMP9, using a monoclonal antibody specific to the active form of gelatinases, inhibited endogenous and experimental lung metastases in the MMTV-PyMT model. Mechanistically, inhibiting MMP9 attenuated migration, invasion, and colony formation and promoted CD8+ T cell infiltration and activation. Interestingly, primary tumor burden was unaffected, suggesting that inhibiting active MMP9 is primarily effective during the early metastatic cascade. These findings suggest that the early metastatic circuit can be disrupted by inhibiting active MMP9 and warrant further studies of MMP9-targeted anti-metastatic breast cancer therapy.

APA, Harvard, Vancouver, ISO, and other styles

40

Tamaki, T., M. Iwakawa, T. Ohno, K. Imadome, M. Sakai, M. Nakawatari, K. Nojiri, H. Tsujii, T. Nakano, and T. Imai. "Anti-Metastatic Effect of Local Carbon-Ion Irradiation in a Highly Metastatic Mouse Model." International Journal of Radiation Oncology*Biology*Physics 69, no. 3 (November 2007): S613. http://dx.doi.org/10.1016/j.ijrobp.2007.07.1927.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Lahlil, Rachid, Fabien Calvo, and Abdel-Majid Khatib. "The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors." Recent Patents on Anti-Cancer Drug Discovery 4, no. 1 (January 1, 2009): 83–91. http://dx.doi.org/10.2174/157489209787002470.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Reddy, Swathi B., Jennifer D. Possick, Harriet M. Kluger, Anjela Galan, and Dale Han. "Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma." Journal of Immunotherapy 40, no. 8 (October 2017): 307–11. http://dx.doi.org/10.1097/cji.0000000000000181.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Jankun, J., A. Aleem, Z. Specht, S. H. Selman, and E. Skrzypczak-Jankun. "46 POSTER Genetically engineered PAI-1 in anti-angiogenic and anti-metastatic therapy." European Journal of Cancer Supplements 4, no. 12 (November 2006): 18. http://dx.doi.org/10.1016/s1359-6349(06)70052-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Keyser, Johanna, Jan Schultz, Kristin Ladell, Lina Elzaouk, Lucie Heinzerling, Jovan Pavlovic, and Karin Moelling. "IP-10-encoding plasmid DNA therapy exhibits anti-tumor and anti-metastatic efficiency." Experimental Dermatology 13, no. 6 (June 2004): 380–90. http://dx.doi.org/10.1111/j.0906-6705.2004.00191.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Zong, Aizhen, Ting Zhao, Yan Zhang, Xinlei Song, Yikang Shi, Hongzhi Cao, Chunhui Liu, et al. "Anti-metastatic and anti-angiogenic activities of sulfated polysaccharide of Sepiella maindroni ink." Carbohydrate Polymers 91, no. 1 (January 2013): 403–9. http://dx.doi.org/10.1016/j.carbpol.2012.08.050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

MAEDA-YAMAMOTO, Mari, Mitsuaki SANO, and Hirofumi TACHIBANA. "Anti-Allergic and Anti-Cancer Metastatic Agents in Green Tea (Camellia sinensis L.)." Kagaku To Seibutsu 41, no. 7 (2003): 442–47. http://dx.doi.org/10.1271/kagakutoseibutsu1962.41.442.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Namuche, Fernando, and Claudio J. Flores. "Anti-VEGF versus Anti-EGFR in the real world in metastatic colorectal cancer." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e16040-e16040. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e16040.

Full text

Abstract:

e16040 Background: The incidence of colorectal cancer (CRC) in Peru has increased in the last decades. But the use of monoclonal antibodies is restricted in our population because of insureance issues. Approximately 20% of patients with CRC already have metastases at diagnosis. There is a lack of data in the benefits of our population with the use of anti-VEGF and anti-EGFR that this study intents to fill. Methods: We retrospectively reviewed the electronic medical records of 58 patients with metastatic CRC, KRAS, NRAS and BRAF wild type from one specialized Peruvian cancer center between 2006 and 2017 Descriptive results for numeric variables were presented as means with standard deviation (SD) or medians with interquartile range (IQR), depending on their distributions; otherwise, we expressed the qualitative variables as numbers with percentages. The survival analysis was performed with Kaplan Meier method for PFS and OS, comparing the curves with Log Rank test. A multivariate analysis was performed using the Cox regression model with the statistically significant variables found in the univariate analysis. Results: There was 29 patients in the anti-EGFR arm, and 29 patients in the anti-VEGF arm. Patients that received first anti-EGFR and then anti-VEGF had better OS [HR, 0.87; 95% CI,0.019-0.811; p < 0.001] than patients that received first anti-VEGF and then anti-EGFR. Multpile Cox regressión analysis demonstrated that metastasectomy, debut with less thant 2 metastasis site, left side tumor, and histologic grade were associated with better OS. Conclusions: Patients with mCRC RAS and BRAF wild type that received anti-EGFR and then anti-VEGF had better OS than patients that received anti-VEGF and then anti-EGFR.

APA, Harvard, Vancouver, ISO, and other styles

48

Xiao, Xian, and Yingjie Jia. "Progress in anti-HER2 targeted therapy of metastatic lung cancer." E3S Web of Conferences 271 (2021): 03074. http://dx.doi.org/10.1051/e3sconf/202127103074.

Full text

Abstract:

Lung cancer is one of the most common malignant tumors in the world and one of the main causes of cancer death. In lung cancer, metastatic stage accounted for a large percentage. It is a global disease affecting human health, with high incidence rate, low malignant degree and other characteristics. After decades of exploration, anti-HER2 targeted therapy in breast has made breakthrough progress, obtained encouraging clinical efficacy, and fully improved the quality of the life of patients. Because of this, more and more researchers are focusing on anti-HER2 in metastatic lung cancer targeting research. For the past few years, new targeted drugs have been constantly developed for anti-HER2 in metastatic lung cancer, and promising data results have been obtained in clinical trials and cohort study. This article provides a review of the clinical research progress of anti-HER2 targeted therapy in metastatic lung cancer in recent years, with a view to further guiding clinical treatment and providing more treatment options for patients.

APA, Harvard, Vancouver, ISO, and other styles

49

Mitsiogianni, Melina, Sotiris Kyriakou, Ioannis Anestopoulos, Dimitrios T. Trafalis, Maria V. Deligiorgi, Rodrigo Franco, Aglaia Pappa, and Mihalis I. Panayiotidis. "An Evaluation of the Anti-Carcinogenic Response of Major Isothiocyanates in Non-Metastatic and Metastatic Melanoma Cells." Antioxidants 10, no. 2 (February 13, 2021): 284. http://dx.doi.org/10.3390/antiox10020284.

Full text

Abstract:

Malignant melanoma is one of the most deadly types of solid cancers, a property mainly attributed to its highly aggressive metastatic form. On the other hand, different classes of isothiocyanates, a class of phytochemicals, present in cruciferous vegetables have been characterized by considerable anti-cancer activity in both in vitro and in vivo experimental models. In the current study, we investigated the anti-cancer response of five isothiocyanates in an in vitro model of melanoma consisting of non-metastatic (A375, B16F-10) and metastatic (VMM1, Hs294T) malignant melanoma as well as non-melanoma epidermoid carcinoma (A431) and non-tumorigenic melanocyte-neighboring keratinocyte (HaCaT) cells. Our aim was to compare different endpoints of cytotoxicity (e.g., reactive oxygen species, intracellular glutathione content, cell cycle growth arrest, apoptosis and necrosis) descriptive of an anti-cancer response between non-metastatic and metastatic melanoma as well as non-melanoma epidermoid carcinoma and non-tumorigenic cells. Our results showed that exposure to isothiocyanates induced an increase in intracellular reactive oxygen species and glutathione contents between non-metastatic and metastatic melanoma cells. The distribution of cell cycle phases followed a similar pattern in a manner where non-metastatic and metastatic melanoma cells appeared to be growth arrested at the G2/M phase while elevated levels of metastatic melanoma cells were shown to be at sub G1 phase, an indicator of necrotic cell death. Finally, metastatic melanoma cells were more sensitive apoptosis and/or necrosis as higher levels were observed compared to non-melanoma epidermoid carcinoma and non-tumorigenic cells. In general, non-melanoma epidermoid carcinoma and non-tumorigenic cells were more resistant under any experimental exposure condition. Overall, our study provides further evidence for the potential development of isothiocyanates as promising anti-cancer agents against non-metastatic and metastatic melanoma cells, a property specific for these cells and not shared by non-melanoma epidermoid carcinoma or non-tumorigenic melanocyte cells.

APA, Harvard, Vancouver, ISO, and other styles

50

Mohammadi, Mozafar, Foroogh Nejatollahi, Younes Ghasemi, and Sayyid Nooreddin Faraji. "Anti-Metastatic and Anti-Invasion Effects of a Specific Anti-MUC18 scFv Antibody on Breast Cancer Cells." Applied Biochemistry and Biotechnology 181, no. 1 (August 27, 2016): 379–90. http://dx.doi.org/10.1007/s12010-016-2218-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Anti-metastatic'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles